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The germinal matrix-intraventricular hemorrhage (GM-IVH) is one of the most
devastating complications of prematurity. The short- and long-term neurodevelopmental
consequences after severe GM-IVH are a major concern for neonatologists. These kids
are at high risk of psychomotor alterations and cerebral palsy; however, therapeutic
approaches are limited. Erythropoietin (EPO) has been previously used to treat several
central nervous system complications due to its role in angiogenesis, neurogenesis and
as growth factor. In addition, EPO is regularly used to reduce the number of transfusions
in the preterm infant. Moreover, EPO crosses the blood-brain barrier and EPO receptors
are expressed in the human brain throughout development. To analyze the role of EPO
in the GM-IVH, we have administered intraventricular collagenase (Col) to P7 mice, as a
model of GM-IVH of the preterm infant. After EPO treatment, we have characterized our
animals in the short (14 days) and the long (70 days) term. In our hands, EPO treatment
significantly limited brain atrophy and ventricle enlargement. EPO also restored neuronal
density and ameliorated dendritic spine loss. Likewise, inflammation and small vessel
bleeding were also reduced, resulting in the preservation of learning and memory
abilities. Moreover, plasma gelsolin levels, as a feasible peripheral marker of GM-IVH-
induced damage, recovered after EPO treatment. Altogether, our data support the
positive effect of EPO treatment in our preclinical model of GM-IVH, both in the short
and the long term.
Keywords: brain atrophy, neuronal loss, erythropoietin, gelsolin, germinal matrix-intraventricular hemorrhage,
preterm infant
INTRODUCTION
Every year there are over 15 million preterm births and ∼7% of these kids suffer long term
neurodevelopmental impairment (Maxwell et al., 2017). The germinal matrix-intraventricular
hemorrhage (GM-IVH) is one of the most common complications observed in the preterm infant
(PTI) (Tan et al., 2018). While the incidence of GM-IVH has declined since the 1990s, due to
improvements in neonatal care, the increased survival of extremely PTI has also contributed to
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maintain the absolute number of GM-IVH very high (Mukerji
et al., 2015). GM-IVH in premature infants arises from the
germinal matrix (GM), which is a complex vascularized layer
rich in immature vessels that surrounds the lateral ventricles,
corresponding with the subventricular zone (SVZ), from where
neurons and glial cells rise during fetal development. GM
microvasculature is extremely fragile due to an abundance
of angiogenic blood vessels that exhibit paucity of pericytes,
immaturity of basal lamina and deficiency of glial fibrillary
acidic protein in the ensheathing astrocytes endfeet (Ballabh,
2010). Therefore, PTI with very low weight birth are more
susceptible to local hemorrhage (Perlman, 2009). The short-
and long-term neurodevelopmental complications in the PTI
with severe or even mild GM-IVH are a major concern,
since these kids are at high risk of neurosensory impairment,
developmental delay, cerebral palsy, deafness, psychomotor
alterations or cerebral palsy (Ballabh, 2010; Mukerji et al., 2015;
Benavente-Fernandez et al., 2018).
Therapeutic approaches focus on enhancing the stability of
GM vasculature and regulating the cerebral blood flow (Ballabh,
2010). Following this idea, erythropoietin (EPO) promotes
the survival, proliferation and differentiation of erythrocyte
progenitors in bone marrow (Lombardero et al., 2011) and is
regularly used in PTI to reduce the number of transfusions. EPO
crosses the blood-brain barrier in a dose-dependent manner and
EPO receptors are expressed in the human brain throughout
development (Kollensperger et al., 2011). Previous studies have
reported that EPO can play a potential role in angiogenesis
and neurogenesis (Lombardero et al., 2011; Juul and Pet, 2015).
Thus, EPO has been used to treat infants with hypoxic-ischemic
encephalopathy (Razak and Hussain, 2019). EPO treatment to
PTI has shown a significant decrease of white matter injury and it
might improve neurodevelopmental outcome of extremely PTI
(Neubauer et al., 2010), although other studies failed to detect
significant benefits, as recent PENUT study has recently reported
(Juul et al., 2020). At present, EpoRepair (Erythropoietin for the
Repair of Cerebral Injury in Very Preterm Infants) trial (Ruegger
et al., 2015) outcomes are also awaited soon. Therefore, the role
of EPO in GM-IVH of the PTI remains unclear. To deepen at
this level, we have induced a GM-IVH in mice by intraventricular
administration of collagenase (Col). After EPO treatment, brain
atrophy and ventricular dilatation were significantly reduced.
Spine and neuronal loss were limited, and overspread small
vessel damage and inflammation were reduced, resulting in the
preservation of learning and memory abilities. Interestingly,
plasma gelsolin levels, as a feasible peripheral marker of
GM-IVH-induced damage, previously observed in other brain
disorders (Xu et al., 2012; Peng et al., 2015; Benavente-Fernandez
et al., 2018), recovered after EPO administration.
MATERIALS AND METHODS
Animals and Treatments
Germinal matrix-intraventricular hemorrhage was induced to
male and female CD1 mice at P7 by intracerebroventricular
(icv) infusion of Col VII-S (batch number: SLBG8830V Sigma,
St Louis, MO) (Segado-Arenas et al., 2018). Mice were
anesthetized with isoflurane and placed in a stereotaxic frame
(David-Kopf, California, United States). 0.3 IU of Col in 1 µl of
TESCA 50 mM (TES buffer, Sigma, ref. T1375, St. Louis, MO,
United States) and calcium chloride anhydrous 0.36 mM (Sigma,
ref. C1016, St. Louis, MO, United States), pH7.4 and 37○C, were
injected with Hamilton syringe in the right ventricle at 0.2 µl/min
(+ 5 more minutes to avoid the retraction of the liquid). Sham
animals received 1 µl of TESCA. Control mice received no
injection. EPO treatment (10.000 or 20.000 IU) (EPO10 and
EPO20) was ip injected on 3 consecutive days: immediately after
completing the lesions, as well as 24 and 48 h later (Kaindl et al.,
2008; Fan et al., 2011; Zhang et al., 2020). A set of mice (10–
12/group) were sacrificed at P14 to analyze the early effects of
EPO and a second set (10–12/group) were aged up to P70 to
assess the long-term effects of EPO treatment. Two weeks before
sacrifice mice underwent behavioral assessment. Animals that
died before the experiments were completed were not included in
subsequent analyses. All animals were maintained in the Animal
Facility of the University of Cadiz under 12 h light/dark cycles
and controlled temperature (21 ± 2○C) with ad libitum access
to food and water. All experimental procedures were approved
by the University of Cadiz Bioethical Committee (Guidelines for
Care and Use of Experimental Animals, European Commission
Directive 2010/63/UE and Spanish Royal Decree 53/2013).
Rotarod
Rotarod (Ugo Basile Srl; Varese, Italia) was used to evaluate motor
skills as described (Segado-Arenas et al., 2018). Mice were placed
in the cylinder 4 min at 4 rpm for habituation purposes. During
the test speed was progressively increased from 4 to 60 rpm, in
1 min, and the time spent on the rotarod was recorded.
Morris Water Maze
A round pool (0.95 m in diameter) was filled with water
(21 ± 1○C) and four equal virtual quadrants were indicated with
geometric cues located in the walls. Experiments were run as
previously described (Infante-Garcia et al., 2017). Briefly, the
scape platform was invisible, 2–3 cm below the surface. The
acquisition started starting 12 days before sacrifice and consisted
of 4 trials/day for 4 days with the submerged platform in the
virtual quadrant number 2. Time limit to locate the platform
was 60 s/trial with an intertrial interval of 10 min. When the
animal did not find the platform it was manually placed on it
for 10 s. Retention 1 commenced 24 h after the finalization of
the acquisition phase, and retention 2 was run 72 h after the
end of the acquisition phase. Retention phases consisted in a
single trial with the platform removed. Time required to locate
the platform (acquisition), percentage of time spent in quadrant
2 (retention) and swimming velocity were analyzed using Smart
software, Panlab (Spain).
Motor Activity and New Object
Discrimination Task
Spontaneous motor activity was analyzed by measuring the
distance traveled by mice for 30 min in a rectangular box
Frontiers in Cell and Developmental Biology | www.frontiersin.org 2 September 2020 | Volume 8 | Article 571258
fcell-08-571258 September 14, 2020 Time: 17:53 # 3
Hierro-Bujalance et al. Erythropoietin for Intraventricular Hemorrhage
(22 × 44 × 40 cm), as described (Infante-Garcia et al., 2016).
The next day mice were placed in the same box and exposed to
two objects (not used afterward), for habituation purposes. On
the third day mice were exposed to two sample trials and a test
trial. On the first sample trial, mice were placed into the center of
the box containing 3 copies of an object arranged in a triangle-
shaped spatial configuration. Mice explored for 5 min and after
30 min delay they received a second sample trial with 4 novel
objects, arranged in a quadratic-shaped spatial configuration, for
another 5 min. Test trial was performed after 30 min delay and
mice were exposed to 2 copies of the object from sample trial 2
(“recent” objects) placed at the same position, and 2 copies of the
object from sample trial 1 (“familiar” objects) placed one of them
at the same position (“familiar non-displaced” object) and the
another in a new position (“familiar displaced” object). “What,”
“where” and “when” integrated episodic memories were analyzed
as described (Infante-Garcia et al., 2016).
Cresyl Violet Staining
We analyzed brain morphology in 6 sections 1 mm apart (from
1.5 to −3.5 mm from Bregma). Sections were dehydrated in
70% ethanol for 15 min. They were stained with cresyl violet
(Sigma, St. Louis, MO, United States) solution (0.5% w/v) for
10 min, as previously described (Ramos-Rodriguez et al., 2017).
Sections were then fixed sequentially in 0.25% acetic acid, 100%
ethanol and xylene for 2 min. Sections were mounted with DPX
(Sigma, St. Louis, MO, United States). Analysis was conducted
blind to the experimental conditions. Images were acquired using
an optical Olympus Bx60 microscope (Japan) with an attached
Olympus DP71 camera and Cell F software (Olympus, Hamburg,
Germany). Cortex and lateral ventricle sizes were measured using
Adobe Photoshop and Image J software.
NeuN and Microglia Immunostaining
NeuN and microglia immunohistochemistry was performed as
described (Infante-Garcia et al., 2015). Anti-NeuN (Chemicon,
CA, United States) (1:200) and anti-Iba1 (Wako, Osaka, Japan)
(1:1000) were used as primary antibodies for neuron and
microglia assessment and incubated overnight at 4○C. Alexa
Fluor 594 or Alexa Fluor 488 (1:1000), respectively, were
used as secondary antibodies. DAPI 1mg/ml (Sigma) (1:3000)
counterstain was used after NeuN immunohistochemistry and
the percentage of NeuN-positive cells (normalized by total cells
stained with DAPI) was quantified in the cortex and the SVZ
using Image J software (Ramos-Rodriguez et al., 2016). Analysis
was conducted blind to the experimental conditions. Number
of microglia cells, individual microglia size and burden were
quantified in the cortex and the SVZ using Image J software
(Infante-Garcia et al., 2016).
Golgi-Cox Staining
Neuron architecture was further analyzed by Golgi-Cox
staining, using Rapid Golgi Stain Kit (FD Neurotechnologies,
United States. Ref: PK401) following manufacturer’s indications
with minor modifications. Brains were maintained in the
kit solutions for 3 weeks, and in 3% agarose liquid solution
afterward. Blocks were cut into 200 µm on a vibratome
(Ted Pella, Inc., California, United States) Sections were
stained as indicated by manufacturer. Sections were dehydrated
with ethanol and mounted with DPX (Sigma, United States).
Neurons were photographed with Olympus U-RFLT microscope
(Olympus, Japan), using MMI Cell Tools software. Neuronal
complexity was analyzed by sholl analysis in 10 µm concentric
circles from neuronal soma. Analysis was conducted blind to
the experimental conditions. Number of crossings every 10 µm
were quantified. Spine density was calculated (spines/10 µm)
(Infante-Garcia et al., 2015). Ratios of curvature were calculated
by dividing the end-to-end distance of a dendrite segment by
the total length between the two segment ends using Image J
software (Ramos-Rodriguez et al., 2017).
Prussian Blue Staining
Consecutive sections to those used for cresyl violet staining
were used for Prussian blue iron staining and neutral red
counterstaining to analyze the presence of hemorrhages
(Infante-Garcia et al., 2015). Images were acquired using an
optical Olympus Bx60 microscope (Japan) with an attached
Olympus DP71 camera and Cell F software (Olympus,
Hamburg, Germany). Analysis was conducted blind to the
experimental conditions. Hemorrhage burden (% of area covered
by hemorrhages) was analyzed in the SVZ (up to 20 µm from
the lateral ventricles), the cortex and the hippocampus using
ImageJ software.
Western Blot for Tau and Akt
We quantified phopho-tau, total tau, phospo-Akt and total
Akt levels in the striatum (including the SVZ), cortex and
hippocampus from all animals under study. Samples were
prepared as previously described (Infante-Garcia et al., 2016).
Briefly, tissue was homogenized in lysis buffer (Cell Signaling,
United States) with a protease/phosphatase inhibitor cocktail
(Sigma, United States). After centrifugation for 5 min, at
15000 g and 4 ○C Bradford (Bio-Rad, Germany) protein assay
was used for protein concentration in supernatants. Proteins
were separated on 10% acrylamide-bisacrylamide gels, followed
by electrophoretic transfer to PVDF membranes (Schleicher
& Schuell, Keene, NH). Antibodies used included: phospho-
tau clone AT8 (1:1000, Fisher Scientific, MA, United States),
phospho-Akt (Ser473) (1:1000) (Cell signaling, United States),
anti-total Akt antibody (1:2000) (cell signaling, United States)
and anti-total tau antibody (1:1000) (DAKO, Denmark).
Optical density was semi-quantified after normalizing to β-actin
(1:2,500,000) (Sigma, United States), using ImageJ software. Data
were represented as percentage of Control values.
Matrix Metalloproteinase 9 and Gelsolin
Plasma Determinations
Plasma matrix metalloproteinase 9 (MMP9) and gelsolin levels
were measured, as feasible markers of central damage, in
the short (P14) and the long (P70) term. We used ELISA
kits for MMP9 (R&D System Corp, MN, United States) and
gelsolin (Cusabio Biotech Co., Wuhan, Hubei Province, China),
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following manufacturer’s indications as previously described
(Segado-Arenas et al., 2018).
Statistical Analysis
One-way ANOVA, followed by Tuckey b test or Tamhane
tests as required, were used. No statistical differences were
detected between Sham and Control groups, therefore all animals
were combined in a single Control group. Two-way ANOVA
was used to analyze the MWM test (groupXday) and neurites
architecture (groupXradius). SPSS v.15 software was used for all
statistical analysis.
RESULTS
EPO Significantly Restores Cognitive
Impairment After Inducing a GM-IVH
The overall compromise in GM-IVH mice for “what,” “where”
and “when” paradigms in the new object discrimination test,
was significant improvement after EPO treatment (“what”
[F(5,225) = 11.30,
∗∗p < 0.01 vs. rest of the groups, ##p < 0.01
vs. Control and Control + EP20], “where” [F(5,249) = 8.36,
∗∗p < 0.01 vs. rest of the groups, ##p < 0.01 vs. Control],
“when” [F(5,258) = 10.95,
∗∗p < 0.01 vs. rest of the groups,
##p < 0.01 vs. Control and Control + EP20]) (Figure 1A). Similar
results were detected in the Morris water maze test. We did
not detect a significant groupXday effect [F(15,1335) = 0.859,
p = 0.611], although further daily assessment revealed differences
on individual acquisition days (day 1 [F(5,371) = 0.878, p = 0.496],
day 2 [F(5,344) = 0.969, p = 0.437], day 3 [F(5,351) = 3.498,
∗∗p = 0.004 vs. rest of the groups], day 4 [F(5,358) = 2.59,
†p = 0.025 vs. Control, Control + EPO10, Control + EPO20 and
Col + EPO20]) (Figure 1B). Also in the retention phase, EPO10
and EPO20 significantly improved Col-induced impairment
(24 h [F(5,85) = 4.29, ††p = 0.002 vs. Control, Control + EPO10,
Control + EPO20 and Col + EPO10]; 72 h [F(5,89) = 2.75,
‡p = 0.025 vs. Control and Col + EPO20]) (Figure 1C). Time
in rotarod ([F(5,57) = 0.611, p = 0.962]), spontaneous motor
activity ([F(5,85) = 0.289, p = 0.917]) and swimming velocity
([F(5,89) = 0.781, p = 0.566]) (Figure 1D) were not affected,
suggesting that alterations in learning and memory were motor-
independent. However, we cannot exclude that larger lesions may
reproduce motor-related alterations, as commonly observed in
patients (Hinojosa-Rodríguez et al., 2017).
EPO Treatment Reduces Brain Atrophy
and Neuronal Alterations After Inducing
a GM-IVH
One week after Col lesions, the size of the ipsilateral hemispheres
was reduced. EPO10 partially limited this effect, that was
completely reversed by EPO20 treatment [F(5,222) = 3.775,
‡‡p = 0.003 vs. Control, Control + EPO10 and Control + EPO20,
##p = 0.003 vs. Control + 10]. The effect was still present at P70
[F(5,174) = 2.83,
∗p = 0.017 vs. rest of the groups] (Figure 2A).
Reduced cortical size was slightly improved by EPO treatment,
although differences did not reach statistical significance in the
FIGURE 1 | EPO treatment significantly reduces GM-IVH cognitive impairment
at P70. (A) Episodic memory is significantly impaired at P70 after inducing a
GM-IVH, and EPO10 and EPO20 treatment counterbalances this limitation for
“what” (**p < 0.01 vs. rest of the groups, ##p < 0.01 vs. Control and
Control + EPO20), “where” (**p < 0.01 vs. rest of the groups, ⊺⊺p < 0.01 vs.
Control) and “when” (**p < 0.01 vs. rest of the groups, ##p < 0.01 vs. Control
and Control + EPO20) paradigms. (B) Spatial memory was also impaired after
Col lesions, when analyzed in the acquisition phase of the Morris water maze,
while EPO treatments significantly reversed this situation on individual days
(day 1: p = 0.496, day 2: p = 0.437, day 3: **p = 0.004 vs. rest of the groups,
day 4: †p = 0.025 vs. Control, Control + EPO10, Control + EPO20 and
Col + EPO20). (C) A similar profile was observed in the retention phase and
EPO10 and EPO20 treatment significantly improved the time spent where the
platform used to be located, 24 (††p = 0.002 vs. Control, Control + EPO10,
Control + EPO20 and Col + EPO10) and 72 h (‡p = 0.025 vs. Control and
Col + EPO20) after completing the acquisition phase. (D) Motor skills were not
affected in rotarod (p = 0.962), spontaneous motor activity (p = 0.917) and
swimming velocity (p = 0.566).
short term (P14) [F(5,222) = 1.107, p = 0.358]. In the long term
(P70) EPO treatment improved cortical atrophy [F(5,175) = 2.95,
‡p = 0.014 vs. Control and Col + EPO10] (Figure 2A). Also, EPO
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FIGURE 2 | Continued
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FIGURE 2 | EPO treatment limits brain atrophy and neuronal alterations after induction of a GM-IVH with Col. (A) Ipsilateral hemisection size was reduced in P14
and P70 mice while EPO treatment limited this effect (P14: ‡‡p = 0.003 vs. Control, Control + EPO10 and Control + EPO20, ##p = 0.003 vs. Control + EPO10; P70:
*p = 0.017 vs. rest of the groups). Differences observed in the cortex did not reach statistical significance at P14 (p = 0.358), although at P70 cortical compromise
was ameliorated by EPO treatment (‡p = 0.014 vs. Control and Col + EPO10). Significant ventricle enlargement was detected at P14 and EPO treatment reversed
this effect (**p = 0.001 vs. rest of the groups) and a similar profile was observed at P70 (††p = 0.001 vs. Control, Control + EPO10, Control + EPO20, Col + EPO20).
(B) Illustrative example of cresyl violet staining showing the ipsilateral ventricle enlargement at P14 and P70, after inducing a GM-IVH, while ventricle size is
maintained in mice treated with EPO. Red line borders the ventricle. Scale bar = 250 µm. (C) At P14, NeuN/DAPI ratio was reduced in the ipsilateral cortex and EPO
treatment improved this situation (#p = 0.034 vs. Control, Control + EPO10 and Col + EPO10). A similar profile was observed at P70 (**p < 0.001 vs. rest of the
groups, ‡‡p < 0.01 vs. Control, Control + EPO10 and Control + EPO20). The SVZ was also affected after Col lesions and EPO treatment significantly improved the
NeuN/DAPI ratio both at P14 and P70 (P14: ††p = 0.002 vs. Control, Control + EPO10, Control + EPO20 and Col + EPO20; P70: ††p = 0.002 vs. Control,
Control + EPO10, Control + EPO20 and Col + EPO20; P70). (D) Illustrative example of NeuN (red)/DAPI (blue) staining in the ipsilateral cortex and SVZ from mice
with GM-IVH induced by Col, where a reduction in NeuN+cells can be observed, while more NeuN+cells are detected after EPO10 and EPO20 treatment. Scale
50 µm. (E) Neuronal complexity was affected by Col lesions and EPO treatment significantly improved this effect at P14 (**p < 0.01 vs. rest of the groups;
‡p = 0.017 vs. Cont + EPO20; ‡‡p = 0.003 vs. Cont + EPO20; ⍑⍑p < 0.01 vs. rest Control and Cont + EPO20) or P70 (**p < 0.01 vs. rest of the groups,
‡‡p < 0.01 vs. Control, Control + EPO20; ††p < 0.01 vs. Control + EPO20, Col + EPO10 and Col + EPO20). (F) Neuron curvature ratio was also impaired after Col
lesions and EPO treatment significantly ameliorated this situation both at P14 (**p < 0.01 vs. rest of the groups) and P70 (**p < 0.01 vs. rest of the groups). (G) Spine
density compromise was also limited after EPO treatment in the ipsilateral hemispheres at P14 (**p < 0.01 vs. rest of the groups, ‡‡p < 0.01 vs. Control,
Control + EPO10 and Control + EPO20, ##p < 0.01 vs. Control and Control + EPO10) and at P70 (**p < 0.01 vs. rest of the groups, ‡‡p < 0.01 vs. Control,
Control + EPO10 and Control + EPO20, ⊺⊺p < 0.01 vs. Control + EPO10). (H) Illustrative example of spines labeled by Golgi-Cox staining. A reduction in spine
density is observed in mice after lesions with Col and this effect is limited by EPO10 and EPO20 treatment at P14 and P70. Scale = 12.5 µm.
treatment completely reversed ventricle enlargement after Col
lesions at P14 [F(5,104) = 4.48,
∗∗p = 0.001 vs. rest of the groups]
(Figures 2A,B). A similar profile was detected with EPO20 at
P70 [F(5,146) = 4.21, ††p = 0.001 vs. Control, Control + EPO10,
Control + EPO20, Col + EPO20] (Figure 2A). No statistical
differences were observed when EPO10 and EPO20 treatments
were compared, and even though a slightly higher improvement
was observed in the cortex from EPO10-treated animals at P70,
an overall better response was observed after EPO20 treatments
in all the other paradigms under study, including cortical size at
P14, as well as hemisection and ventricle sizes at P14 and P70.
At P14 NeuN/DAPI ratio was reduced in the ipsilateral cortex
after Col lesions, and EPO treatment improved this situation
[F(5,3428) = 2.41, #p = 0.034 vs. Control, Control + EPO10
and Col + EPO10] (Figures 2C,D). A similar outcome was
observed at P70 [F(5,2996) = 14.35,
∗∗p < 0.001 vs. rest
of the groups, ‡‡p < 0.01 vs. Control, Control + EPO10
and Control + EPO20] (Figures 2C,D). EPO20 treatment
also improved NeuN/DAPI compromise in the SVZ at P14
[F(5,987) = 3.82, ††p = 0.002 vs. Control, Control + EPO10,
Control + EPO20 and Col + EPO20] and P70 [F(5,977) = 4.73,
††p = 0.002 ‡vs. Control, Control + EPO10, Control + EPO20
and Col + EPO20] (Figures 2C,D).
Neuronal architecture was also altered after GM-IVH.
Analysis of neurites intersections by sholl analysis after Golgi-
Cox staining revealed a groupXradius distance effect by 2 way
ANOVA in the ipsilateral hemisphere at P14 [F(25,3997) = 1.54,
p = 0.041]. Further assessment of individual distances revealed
and overall improvement in mice treated with EPO10 and
EPO20 (<10 µm [F(5,670) = 7.59,
∗∗p < 0.01 vs. rest of the
groups]; 10–20 µm [F(5,669) = 7.28,
∗∗p < 0.01 vs. rest of
the groups]; 20–30 µm [F(5,658) = 5.08,
∗∗p < 0.01 vs. rest
of the groups]; 30–40 µm [F(5,656) = 6.60, ⍑⍑p < 0.01 vs.
Control and Cont + EPO20]; 40–50 µm [F(5,671) = 3.60,
‡‡p < 0.01 vs. Cont + EPO20]; 50–60µm [F(5,673) = 3.87,
‡‡p = 0.002 vs. Cont + EPO20] (Figure 2E). At P70, we did
not detect a significant groupXradius effect by 2 way ANOVA
[F(25,3779) = 0.964, p = 0.514]. Assessment of individual distances
revealed that EPO treatment limited neuronal simplification
(<10 µm [F(5,456) = 11.10,
∗∗p < 0.01 vs. rest of the
groups, ‡‡p < 0.01 vs. Control, Control + EPO20]; 10–20 µm
[F(5,668) = 10.48, ∗∗p < 0.01 vs. rest of the groups; ††p < 0.01
vs. Control + EPO20, Col + EPO10 and Col + EPO20]; 20–
30 µm [F(5,655) = 8.77,
∗∗p < 0.01 vs. rest of the groups];
30–40 µm [F(5,662) = 6.60,
∗∗p < 0.01 vs. rest of the groups];
40–50 µm [F(5,664) = 8.42,
∗∗p < 0.01 vs. rest of the groups];
50–60 µm [F(5,674) = 6.51,
∗∗p < 0.01 vs. rest of the groups])
(Figure 2E). Neuron curvature ratio was also impaired after
Col lesions and EPO treatment significantly ameliorated this
situation both at P14 ([F(5,813) = 5.78,
∗∗p < 0.01 vs. rest
of the groups]) and P70 ([F(5,565) = 5.901,
∗∗p < 0.01 vs.
rest of the groups]) (Figure 2F). Spine density (number of
spines/10 µm) was also restored after EPO treatment in the
short (P14 [F(5,3985) = 27.55,
∗∗p < 0.01 vs. rest of the groups,
‡‡p < 0.01 vs. Control, Control + EPO10 and Control + EPO20,
##p < 0.01 vs. Control and Control + EPO10]) and the long
term (P70 [F(5,1091) = 15.44,
∗∗p < 0.01 vs. rest of the groups,
‡‡p < 0.01 vs. Control, Control + EPO10 and Control + EPO20, –
p < 0.01 vs. Control + EPO10]) (Figures 2G,H).
EPO Treatment Reduces Central
Bleeding in a GM-IVH Model
Increased hemorrhage burden in the SVZ after Col lesions was
completely reversed by EPO10 and EPO20 administration at
P14 [F(5,112) = 11.089,
∗p = 0.013 vs. rest of the groups]
and P70 [F(5,125) = 11.089,
∗∗p < 0.01 vs. rest of the
groups], due to a reduction in the number of individual
hemorrhages (P14: [F(5,111) = 2,76,
∗p = 0.021 vs. rest of
the groups]; P70: [F(5,127) = 15.36,
∗∗p < 0.01 vs. rest of
the groups], while individual hemorrhage size was not affected
(P14: [F(5,1111) = 1.55, p = 0.169] P70 [F(5,149) = 0.967,
p = 0.440]) (Figure 3A). A similar profile was observed in
the cortex and increased hemorrhage burden was reduced by
EPO (P14 [F(5,271) = 12.16,
∗∗p < 0.01 vs. rest of the groups];
P70 [F(5,277) = 6.64,
∗∗p < 0.01 vs. rest of the groups]),
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FIGURE 3 | EPO treatment reduces vascular damage and inflammation after inducing a GM-IVH. (A) Hemorrhage burden was significantly increased in the SVZ after
Col lesions and EPO10 and EP20 treatments reversed this effect, both in the short (P14) and the long term (P70) (P14: *p = 0.013 vs. rest of the groups and P70:
**p < 0.01 vs. rest of the groups). The number of individual hemorrhages was reduced after EPO treatment (P14: *p = 0.021 vs. rest of the groups; P70: **p < 0.01
vs. rest of the groups), while individual hemorrhage size was not affected (P14: p = 0.169]; P70: p = 0.440]. When we analyzed the cortex we observed a similar
profile and increased hemorrhage burden, after Col lesions, was reduced by EPO treatment (P14: **p < 0.01 vs. rest of the groups; P70: **p < 0.01 vs. rest of the
groups), due to a reduction in the number of individual hemorrhages after the treatment (P14: **p < 0.01 vs. rest of the groups; P70: ††p < 0.01 vs. Control,
Control + EPO10, Control + EPO20 and Col + EPO20), while hemorrhage size was not affected (P14: p = 0.123; P70: p = 0.296). In the hippocampus, increased
hemorrhage burden in the ipsilateral side was reversed by EPO administration (P14: *p = 0.02 vs. rest of the groups; P70: **p < 0.01 vs. rest of the groups,
##p < 0.01 vs. Control + EPO10 and Control + EPO20). The number of individual hemorrhages was reduced after the treatment (P14: †p = 0.046 vs. Control,
Control + EPO10, Control + EPO20 and Col + EPO10; and P70: **p < 0.01 vs. rest of the groups, ††p < 0.01 vs. Control, Control + EPO10, Control + EPO20,
Col + EPO20) while hemorrhage size was not affected (P14: p = 0.005, no further differences detected; P70: p = 0.270). (B) Illustrative images of cortical Prussian
blue staining and Congo red counterstain for hemorrhages. Increased bleeding after Col lesions was reduced by EPO treatment both at P14 and P70. Green arrow
point at individual cortical hemorrhages. Scale bar = 250 µm. Bottom panels show increased hemorrhage burden in the SVZ from Col-lesioned animals, both at P14
and P70. Scale bar = 25 µm. (C) Microglia activation after Col lesions was reduced by EPO treatment at P14 and P70 in the SVZ (P14: ##p = 0.003 vs. Control and
Control + EPO20; P70: **p < 0.01 vs. rest of the groups), cortex (P14: ‡‡p < 0.01; P70: **p < 0.01 vs. rest of the groups; ##p < 0.01 vs. Control) and hippocampus
(P14: ‡‡p < 0.01 vs. Control, Control + EPO10 and Control + EPO20; P70: p = 0.098). (D) Illustrative example of microglia immunostaining for IBA-1 (green) in the
SVZ and cortex from all groups under study. Increased microglia activation can be observed in Col-treated mice while EPO treatment significantly reduces this effect.
Scale bar = 50 µm.
number of individual hemorrhages was reduced by EPO (P14
[F(5,266) = 20.75,
∗∗p < 0.01 vs. rest of the groups]; P70
[F(5,228) = 10.01, ††p < 0.01 vs. Control, Control + EPO10,
Control + EPO20 and Col + EPO20]) while hemorrhage size was
not affected (P14 [F(5,553) = 1.74, p = 0.123]; P70 [F(5,690) = 1.22,
p = 0.296]) (Figures 3A,B). The hippocampus showed a similar
trend (hemorrhage burden: P14 [F(5,124) = 2.79,
∗p = 0.02
vs. rest of the groups]; P70 [F(5,103) = 13.01
∗∗p < 0.01
vs. rest of the groups, ##p < 0.01 vs. Control + EPO10 and
Control + EPO20]; number of hemorrhages: P14 [F(5,124) = 2.33,
†p = 0.046 vs. Control, Control + EPO10, Control + EPO20
and Col + EPO10] and P70 [F(5,116) = 15.80,
∗∗p < 0.01 vs.
rest of the groups, ††p < 0.01 vs. Control, Control + EPO10,
Control + EPO20, Col + EPO20] and hemorrhage size: P14
[F(5,285) = 3.42, p = 0.005, no further differences detected], P70
[F(5,286) = 1.28, p = 0.270]).
Inflammation Is Reduced in a GM-IVH
After EPO Treatment
After Col lesions, microglia burden was analyzed in the SVZ,
cortex and hippocampus at P14 and P70. Col-induced GM-
IVH increased microglia burden, and EPO treatment limited
this effect when we analyzed the SVZ at P14 [F(5,817) = 3.63,
##p = 0.003 vs. Control and Control + EPO20] and at
P70 [F(5,768) = 4.71,
∗∗p < 0,01 vs. rest of the groups]
(Figures 3C,D). We observed a similar profile when we analyzed
the cortex, and EPO treatment reduced microglia burden at P14
([F(5,3870) = 12.66, ‡‡p < 0,01 vs. Control, Control + EPO10 and
Control + EPO20]) and P70 ([F(5,3521) = 18.122,
∗∗p < 0,01 vs.
rest of the groups; ##p < 0.01 vs. Control]) (Figures 3C,D). In
the hippocampus, EPO treatment successfully reduced microglia
burden at the highest dose (EPO20) at P14 [F(5,775) = 14.78,
‡‡p < 0.01 vs. Control, Control + EPO10 and Control + EPO20],
whereas differences did not reach statistical significance at P70
[F(5,687) = 1.86, p = 0.098]) (Figure 3C).
EPO Treatment Reduces Tau
Phosphorylation in a GM-IVH Murine
Model
Increased tau phosphorylation after Col lesions was reduced
by EPO treatment at P14, however, differences did not reach
statistical significance (striatum [F(5,25) = 1.61, p = 0.193];
cortex: [F(5,25) = 0.275, p = 0.922] and hippocampus:
[F(5,24) = 0.8889, p = 0.504]) (Figures 4A,B). At P70 EPO
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FIGURE 4 | EPO treatment reduces tau and Akt phosphorylation after Col lesions. (A) Increased tau phosphorylation after Col lesions was reduced after EPO
treatment at P14 although differences did not reach statistical significance (striatum: p = 0.193; cortex: p = 0.922 and hippocampus: p = 0.504]). A similar profile
was observed when we analyzed animals in the long term (P70) (striatum: #p = 0.023 vs Control + EPO20; cortex: p = 0.658 and hippocampus: p = 0.522).
(B) Illustrative example of phospho-tau/total tau striatum westerns blots at P14 and P70, showing an increased phosphorylation after Col lesions at P70, that is
reduced by EPO treatment. (C) Increased phosphor-Akt/total Akt ratios after Col lesions were reduced by EPO treatment in the ipsilateral hemisphere although
differences did not reach statistical significance at P14 (striatum: p = 0.127; cortex: p = 0.552; hippocampus: p = 0.055) or at P70 (striatum: p = 0.931; cortex:
p = 0.425; hippocampus: p = 0.475). (D) Illustrative example of striatum phosphor-Akt/total Akt western blots at P14 and P70, after EPO treatments.
limited tau hyperphosphorylation in the striatum [F(5,26) = 3.17,
#p = 0.023 vs. Control + EPO20]) and while a similar
profile was observed in the hippocampus, differences did not
reach statistical significance [F(5,24) = 0.860, p = 0.522]. No
differences were observed in the cortex at P70 [F(5,24) = 0.659,
p = 0.658] (Figures 4A,B).
Effect of EPO Treatment on Akt
Phosphorylation in a GM-IVH Murine
Model
We detected a slight increase in phosphoAkt/total Akt ratios
after inducing a GM-IVH. EPO treatment reduced this effect
in the ipsilateral hemisphere although no differences were
observed at P14 (striatum [F(5,25) = 1.91, p = 0.127]; cortex
[F(5,25) = 0,813, p = 0.552], hippocampus [F(5,24) = 2.54,
p = 0.055]) (Figures 4C,D) or P70 (striatum P70 [F(5,30) = 0.260,
p = 0.931]; cortex [F(5,22) = 1.029, p = 0.425]; hippocampus
[F(5,31) = 0.930, p = 0.475]) (Figures 4C,D).
EPO Treatment Reduces Alterations in
Plasma Markers After Col Lesions
MMP9 plasma levels were not significantly affected (P14
[F(5,63) = 0.689, p = 0.633]; P70 [F(5,63) = 0.953, p = 0.453])
(Figure 5A). On the other hand, gelsolin levels were reduced
after Col lesions at P14, as described (Segado-Arenas et al.,
2018), while EPO treatment counterbalanced this situation
[F(5,60) = 4.372,
∗∗p = 0.002 vs. rest of the groups]. Differences
were no longer significant in the long term (P70 [F(5,60) = 0.770,
p = 0.575]) (Figure 5B).
DISCUSSION
Germinal matrix-intraventricular hemorrhage remains one of the
most serious complications of the PTI (Mukerji et al., 2015)
and has no successful treatment (Brouwer et al., 2014). Most
of the current approaches have focused on strengthening the
GM or stabilizing brain blood flow to prevent the GM-IVH
(Ballabh, 2010). Prenatal glucocorticoids (Carson et al., 2016),
indomethacin (Fowlie and Davis, 2003) or phenobarbital have
been proposed as feasible treatments. On the other hand, it
has also been suggested that stem cells therapy might provide
an encouraging approach. Nevertheless, some limitations still
exist, such as choosing the right cells, the appropriate patients
or routes of administration. Also, safety issues remain to be
solved and significantly limit the use of stem cells in the clinic
(Chang et al., 2017).
Recombinant human EPO is regularly used to prevent or
treat anemia of the PTI and studies in patients reveal that
the early use of erythropoiesis-stimulating agents may reduce
the incidence of GM-IVH and be neuroprotective (Neubauer
et al., 2010). The doses of EPO used in our study are high
when compared with those used in PTI patients (Juul et al.,
2020). Dose conversion remains a relevant issue in experimental
animal models (for review Nair and Jacob, 2016) and doses
tend to be reduced as we ascend in the phylogenetic scale. The
doses used in our study are in the range of those previously
used in other neonate murine models (Kaindl et al., 2008; Fan
et al., 2011; Hoeber et al., 2016; Zhang et al., 2020). Moreover,
safety of EPO has been previously addressed with large doses
of EPO, even in extremely low weight infants (McAdams et al.,
2013). Erythropoiesis-stimulating agents may also have a positive
effect on neurodevelopmental impairment of the PTI (for review
see Ohlsson and Aher, 2017, 2020). Following this idea, and
while results remain controversial, EPO may specifically provide
beneficial effects on the neurodevelopment outcome in the
PTI without severe adverse side effects (Wang et al., 2015).
Nevertheless later updates on the beneficial effects of EPO remain
controversial and the promising, but conflicting, results related to
EPO as a neuroprotective agent require further study (Ohlsson
and Aher, 2020). Moreover, several clinical trials have been
in progress in the last few years assessing EPO in neonatal
populations (Maxwell et al., 2017). The multicenter (19 sites,
Frontiers in Cell and Developmental Biology | www.frontiersin.org 8 September 2020 | Volume 8 | Article 571258
fcell-08-571258 September 14, 2020 Time: 17:53 # 9
Hierro-Bujalance et al. Erythropoietin for Intraventricular Hemorrhage
FIGURE 5 | Effect of EPO treatment on peripheral markers of GM-IVH. (A) EPO treatment does not affect MMP9 plasma levels at P14 (p = 0.633) or P70
(p = 0.453). (B) EPO treatment restores plasma gelsolin levels after inducing a GM-IVH in the short term, while differences are no longer detected in the long term
(P70) (P14 **p = 0.002 vs. rest of the groups, P70 p = 0.575).
30 hospitals), randomized, double-blind trial of EPO, PENUT
(Preterm Epo Neuroprotection), has recently shown limited
effects on very PTI after ≈2 years follow up. The PENUT study
is an extremely relevant study on the field, however, individual
groups were not analyzed and it remains possible that cognitive
and physical problems might become evident later in life (Juul
et al., 2020). Following this idea, Volpe (2020) has commented
this aspect as a main limitation, also acknowledged in the study,
since cognitive testing at 2 years of age is not as reliable as
testing at later ages. In this sense, other studies comparing
early assessments (before 3 years of age) with later cognitive
tests at school age, showed a relatively low pooled sensitivity
(55%) of early assessments to identify school-age cognitive
deficits. Moreover, EPO is especially successful in protecting
preoligodendrocytes. White matter development is an active
process that continues well after infancy and it’s closely related
to specific cognitive functions that may be affected at later stages.
Therefore Volpe suggests the necessity of testing longer duration
of treatment, reaching full-term equivalent age or even longer
(Volpe, 2020). A previous meta-analysis has also showed that
that prophylactic EPO improves cognitive development (Fischer
et al., 2017) and early EPO treatment may decrease the rates of
necrotizing enterocolitis as well as brain complications, including
IVH and periventricular leukomalacia (Ohlsson and Aher, 2017).
Moreover, it seems that an early high dose of EPO has a weak
but widespread effect on brain structural connectivity network
in very PTI, supporting a trophic effect of EPO that increases
network segregation, predominantly in local connections (Jakab
et al., 2019). Nevertheless, recent updates report a limited
success of EPO treatment (Ohlsson and Aher, 2020), supporting
further studies given the controversial outcomes. Altogether, and
given the present results, EPO administration is not currently
recommended because the benefits are not fully established
(Ohlsson and Aher, 2017; Fleiss and Gressens, 2019) and
the underlying mechanisms and specific effects in the GM-
IVH have not been studied in depth. At this point, as it
has previously been stressed out there are no preclinical data
showing the neuroprotective effects of EPO in a model of
encephalopathy of prematurity, limiting the understanding of
the best paradigm to deliver neuroprotection in this population
(Fleiss and Gressens, 2019).
In order to help disentangle the effects of EPO treatment, we
have treated with EPO a recently characterized murine model of
GM-IVH of the preterm newborn, induced by Col administration
(Segado-Arenas et al., 2018). While evident limitations persist,
it is noteworthy that this model reproduces morphological,
functional and neurodevelopmental alterations of the GM-IVH.
Col administration in the lateral ventricle breaks the extracellular
matrix that surrounds the GM capillaries, increases blood brain
barrier permeability and induces bleeding (Segado-Arenas et al.,
2018). Moreover Col administration to neonate (P7) CD1
mice results in brain atrophy, ventricle enlargement, increased
inflammation, widespread small vessel damage and cognitive
impairment that are still detected in the adulthood (Segado-
Arenas et al., 2018), as observed in the clinic. EPO treatment,
at 10.000 or 20.000 IU/Kg significantly ameliorated learning and
memory alterations in the long term (P70). Although the fact that
young P14 mice cannot be assessed at cognitive level is limiting,
early histopathological complications at P14 match the functional
outcomes at P70. In our hands, motor-related alterations are
limited with this approach, and we cannot exclude that larger
lesions could reproduce motor impairment as regularly observed
in the clinic (Hinojosa-Rodríguez et al., 2017). While the studies
on the effect of EPO in neonates with GM-IVH are limited
(Ruegger et al., 2015), our data are in accordance with a seminal
study by Neubauer et al. (2010) in which children with GM-
IVH showed a remarkably strong benefit from EPO treatment
at 5 years of age and later. While some controversy persists
(Leuchter et al., 2014; Natalucci et al., 2016), these observations
are also in line with studies showing that EPO improves cognitive
outcomes in PTI both early in life (18–22 months) (Wang et al.,
2015) and once the patients reach school (3.5–4 years old)
(Ohls et al., 2016).
Morphopathological changes after Col lesions resemble those
detected in PTI with GM-IVH, including complicated post-
hemorrhagic ventricular dilatation (Brouwer et al., 2014).
Moreover, these changes are directly associated with an overall
brain atrophy and bad prognosis (Saliba et al., 1990). Also,
the neuronal population is compromised around the ventricles
(Georgiadis et al., 2008), as well as in areas located far from the
lesion area, such as the cortex, supporting an overspread long-
lasting damage, as previously described (Segado-Arenas et al.,
2018). The mechanisms implicated have not been elucidated,
and atrophy has been attributed to both loss of ischemic
infracted tissue and defective development of the damaged
areas (Semple et al., 2013). In our hands, curvature ratio, as
an indicator of neuron wellness (Infante-Garcia et al., 2015),
neuronal complexity and spine density were compromised
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in mice after GM-IVH, while EPO treatment rescued these
alterations, supporting its neurotrophic role (Juul and Pet, 2015)
and neuroprotective effect at different levels. To our knowledge,
the role of EPO in a model of GM-IVH of the PTI has not been
previously assessed, however, in line with our observations, EPO
protects against striatum atrophy, hippocampus injury, and white
matter loss in a model of hypoxia-ischemia in neonatal mice
(Fan et al., 2011).
We observed an increase of widespread hemorrhages after
Col lesions, as previously described (Segado-Arenas et al.,
2018). Hemorrhage density and burden seem to be higher
in the SVZ at later ages (P70), suggesting that small vessel
damage might be a long-term consequence of the GM-IVH. We
never addressed age differences, since P14 brains are extremely
immature (Semple et al., 2013) and can hardly be compared
to fully developed P70 brains. The fact that EPO treatment
successfully counterbalances this effect might be attributed to
its role in erythropoiesis, that requires iron utilization, and
therefore reduces the potential toxicity of free iron (Juul and
Ferriero, 2014). Likewise, EPO promotes revascularization in
hypoxic-ischemic neonatal models (Iwai et al., 2007). Previous
studies have also shown that EPO induces angiogenesis through
the production of vascular endothelial growth factor, protecting
capillaries (Wang et al., 2008) and bood brain barrier integrity
(Marti et al., 2000). Col lesions also provoked an inflammatory
response that is commonly observed in PTI (Juul and Ferriero,
2014). The antioxidant and anti-inflammatory effects of EPO
have been widely assessed in different models of brain insult
(Wei et al., 2017) and in our hands EPO treatment significantly
reduces microglia activation after GM-IVH induction. Iba-1
immunostatining is classically used to label microglia, however,
we only analyzed microglia burden and it is possible that
more complex inflammatory changes are not covered with our
approach. Previous studies have shown that microglia express
EPO receptors (Nagai et al., 2001) and that EPO may reduce
motility, as an important feature of microglial pathological
reaction to damage (Mitkovski et al., 2015), while promoting the
polarization of microglia toward the protective M2 phenotype
(Wei et al., 2017).
Hyperphosphorylated tau is a toxic pathological hallmark of
neurodegenerative disorders, increased in this and other models
with central hemorrhages (Infante-Garcia et al., 2016; Segado-
Arenas et al., 2018). Col lesions increased tau phosphorylation
in the striatum, as the closest area to the ventricle. EPO
slightly reduced this situation in the striatum and no effect was
detected in the cortex or the hippocampus. Previous studies have
reported that EPO, alone or combined with other treatments,
may reduce tau phosphorylation associated to different cognitive
disorders (Kang et al., 2010; Vinothkumar et al., 2019). Even
though glycogen synthase kinase-3β inhibition reduces tau
phosphorylation (Maqbool et al., 2016), enhances myelination,
improves clinical recovery in a model of GM-IVH (Dohare et al.,
2018a) and restores altered neurogenesis in preterm patients with
intraventricular hemorrhage (Dohare et al., 2018b), the narrow
effect in our studies limits further conclusions at this level. Also,
since Akt is implicated in cell cycle regulation, cell survival and
apoptosis, it is feasible that the beneficial effects observed after
EPO treatment could be Akt-mediated. Previous studies have
shown that Akt phosphorylation is increased in subarachnoid
hemorrhage models (Guo et al., 2018). It has also been pointed
out that EPO, in combination with insulin-like growth factor-1,
may contribute to increase Akt activation (Kang et al., 2010).
However, we only observed a slight increase in phopho-Akt levels
after inducing a GM-IVH.
MMP9 levels were not affected, in agreement with previous
studies (Segado-Arenas et al., 2018). On the other hand, plasma
gelsolin levels were significantly reduced in mice after GM-
IVH, as previously reported (Segado-Arenas et al., 2018). Plasma
gelsolin is a feasible peripheral marker of central complications
and low plasma gelsolin levels have been associated with poor
outcomes in adult brain hemorrhagic alterations (Chou et al.,
2011), in premature infants (Kose et al., 2014) and other
newborn complications (Benavente-Fernandez et al., 2018). EPO
treatment significantly restores plasma gelsolin levels, suggesting
that its positive effects at central level are also detected in the
periphery and reinforcing further studies on the utility of plasma
gelsolin as a prognostic tool.
CONCLUSION
Erythropoietin is a safe, already approved drug to treat other
complications of the PTI. Altogether, our data support further
assessment of EPO (Volpe, 2020) as a feasible treatment to
protect against central complications associated to GM-IVH in
the short (P14) and the long term (P70). Moreover we provide
evidence of gelsolin, as a feasible marker for a devastating
disease. Ultimately, our study helps to further understand the
pathophysiology underlying the IVH of the preterm newborn
and the best paradigms to define new protection for PTI
(Fleiss and Gressens, 2019).
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